Investigational immunotherapeutics for B-cell malignancies. - Wikidata - awgldk - TriplyDB

Investigational immunotherapeutics for B-cell malignancies.

Investigational immunotherapeutics for B-cell malignancies.

http://www.wikidata.org/entity/Q37667386

about

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.The future role of monoclonal antibody therapy in childhood acute leukaemias.Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.A new cellular weapon to kill leukaemic B-cells.Relapsed Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type.Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.

P2860

Q33828575-FFF0D33E-319C-44AC-A8E2-0EA99B7808EC Q33895804-E1832CC3-0F26-4D55-894D-50A9A11E3AF2 Q34165735-39EC630F-5B82-4F0A-9A3F-8CF28511B023 Q35183874-12192C98-0E36-40D9-9B4E-CDC7F4ADDBC6 Q37913356-7B7A8142-20DF-47AF-BF1A-28CF2120F59F Q38033600-0F596D26-C483-407D-A184-E98C5BDC81FA Q42427577-46F2DAA0-E97D-4D79-8284-FAA497EB09B1 Q42544252-626CC5DF-8AB4-40DE-828B-12895DBA42B4 Q47138760-1F89C536-208B-4417-8796-3DE9FD4726D2 Q50027149-9FA3AED9-0777-45AC-8141-310FF66C94AF

P2860

Investigational immunotherapeutics for B-cell malignancies.

http://www.wikidata.org/entity/Q37667386

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Investigational immunotherapeutics for B-cell malignancies.

@en

Investigational immunotherapeutics for B-cell malignancies.

@nl

type

label

Investigational immunotherapeutics for B-cell malignancies.

@en

Investigational immunotherapeutics for B-cell malignancies.

@nl

prefLabel

Investigational immunotherapeutics for B-cell malignancies.

@en

Investigational immunotherapeutics for B-cell malignancies.

@nl

P1433

Q37667386-0C7E4243-BB81-4564-97B0-CD0340AF9E6B

P1476

Q37667386-A7006D86-98FE-48BA-BA9A-5A7FDEE38A8D

P2093

Q37667386-C59691BF-F0BF-4E7A-9068-A51214BEEF1B

P2860

Q37667386-02338929-B10A-4418-A952-67EC9A635D3C

Q37667386-084E34E0-2EA2-406E-B12A-8F3706F6BA0D

Q37667386-0A345AA6-8B16-497D-982E-17E1E14793A9

Q37667386-116622AA-1CE6-4992-902A-EF1CF678D22C

Q37667386-17294A3E-D72A-4620-BDB3-7E5DFA92254C

Q37667386-23CF9234-3C73-4270-BB29-D8820ABCDBA8

Q37667386-249E332E-B5D4-4119-A949-FCEE8A941412

Q37667386-264620B0-AC91-4617-983E-3C243A930C3F

Q37667386-2AAB0696-9427-4158-83A0-5364A7B4CE50

Q37667386-2C69CECD-DAD4-445B-83EF-365AC466D10E

P304

Q37667386-55EBA0C7-7EB2-4CD5-AA6E-5503927B8857

P31

Q37667386-50DB94F4-5064-4B31-8C64-259593C88E62

P356

Q37667386-7ABF25F5-664C-4C05-90B1-DC3FB4FB8376

P407

Q37667386-7699A54D-66B6-4DC7-9BDC-7C15FCDAF970

P433

Q37667386-C4954BEC-1298-4026-8AF6-99C247400347

P478

Q37667386-DCBBC68F-5980-4B71-84A0-FD8915CDDC90

P50

Q37667386-05D4F79F-D8F8-4FCD-96FB-9919E1EF3022

Q37667386-F009BAC6-6524-4CC9-9A84-53627896209E

P577

Q37667386-06F43491-30EE-43FA-9493-F3CD0F7B83D8

P698

Q37667386-4BF73A64-47D2-420F-BEE0-CE41B41F8270

P921

Q37667386-3DDB560C-FA7A-46C3-A89A-2FFC8ACA3BD0

P932

Q37667386-79B201A4-748C-4ADB-A679-2A8D2051B7EA

P356

JCO.2009.22.8254

P1433

Journal of Clinical Oncology

P1476

Investigational immunotherapeutics for B-cell malignancies.

@en

P2093

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

A regulatory role for CD37 in T cell proliferation

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

P304

884-892

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.22.8254

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

William G Wierda

P577

2010-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20048186

http://www.w3.org/2001/XMLSchema#string

P921

P932

4872311

http://www.w3.org/2001/XMLSchema#string